Rafferty Asset Management
CRL icon

Rafferty Asset Management’s Charles River Laboratories CRL Stock Holding History

Rafferty Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Buy
8,246
+2,742
+50% +$488K ﹤0.01% 657
2026
Q1 		$949K Sell
5,504
-2,025
-27% -$375K ﹤0.01% 783
2025
Q4 		$1.5M Sell
7,529
-52
-0.7% -$9.43K 0.01% 713
2025
Q3 		$1.19M Sell
7,581
-27
-0.4% -$4.29K ﹤0.01% 759
2025
Q2 		$1.15M Buy
7,608
+1,205
+19% +$161K ﹤0.01% 737
2025
Q1 		$964K Sell
6,403
-457
-7% -$76.6K ﹤0.01% 751
2024
Q4 		$1.27M Buy
6,860
+360
+6% +$69.3K ﹤0.01% 746
2024
Q3 		$1.28M Sell
6,500
-507
-7% -$105K ﹤0.01% 745
2024
Q2 		$1.45M Buy
7,007
+69
+1% +$15.6K 0.01% 728
2024
Q1 		$1.88M Buy
6,938
+1,717
+33% +$410K 0.01% 700
2023
Q4 		$1.23M Sell
5,221
-127
-2% -$25K 0.01% 795
2023
Q3 		$1.05M Buy
5,348
+389
+8% +$79.9K 0.01% 780
2023
Q2 		$1.04M Buy
4,959
+407
+9% +$81K 0.01% 808
2023
Q1 		$919K Sell
4,552
-1,348
-23% -$305K 0.01% 818
2022
Q4 		$1.29M Buy
5,900
+974
+20% +$213K 0.01% 694
2022
Q3 		$969K Buy
4,926
+3,693
+300% +$797K 0.01% 692
2022
Q2 		$264K Sell
1,233
-309
-20% -$75.5K ﹤0.01% 957
2022
Q1 		$438K Sell
1,542
-155
-9% -$47.8K ﹤0.01% 1039
2021
Q4 		$639K Buy
1,697
+90
+6% +$35K ﹤0.01% 1015
2021
Q3 		$663K Buy
1,607
+567
+55% +$235K ﹤0.01% 980
2021
Q2 		$385K Buy
+1,040
New +$347K ﹤0.01% 1121
2020
Q3 		– Sell
-3,510
Closed -$612K – 966
2020
Q2 		$612K Buy
+3,510
New +$560K 0.01% 665
2016
Q1 		– Sell
-6,872
Closed -$553K – 526
2015
Q4 		$553K Buy
+6,872
New +$496K 0.07% 338
2014
Q4 		– Sell
-5,067
Closed -$303K – 354
2014
Q3 		$303K Buy
+5,067
New +$290K 0.03% 255

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Rafferty Asset Management's CRL Position: Q2 2026 in Review

Rafferty Asset Management increased its Charles River Laboratories (CRL) stake by 50% in Q2 2026, buying an estimated $488K and bringing the position to 8,246 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #657.

Rafferty Asset Management first reported a position in CRL in Q3 2014 and has held it in 24 quarters since. The position peaked at $1.88M in Q1 2024. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Rafferty Asset Management held 8,246 shares of Charles River Laboratories worth $1.87M as of Q2 2026.
  • Rafferty Asset Management bought 2,742 Charles River Laboratories shares in Q2 2026, an estimated $488K.
  • Charles River Laboratories made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #657 holding.
  • Rafferty Asset Management first reported a position in Charles River Laboratories in Q3 2014 and has held it in 24 quarters since.
  • Rafferty Asset Management's Charles River Laboratories position peaked at $1.88M in Q1 2024.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.